The study on vitamin D3 spray absorption demonstrated:

  • laboratory test have shown that the LYLsunD3 LYLmicro™ formula is safe and able to quickly enter the bloodstream.

The randomized, placebo controlled, independent study demonstrated:

  • LYLsunD3 LYLmicro™ taken twice a day over the course of one month increases overall blood levels of vitamin D by 132%. 
  • at the end of the study overall blood levels of vitamin D had increased for 92% of subjects who were taking LYLsunD3 LYLmicro™ twice a day.

 The clinical study at Pauls Stradiņš Clinical University Hospital demonstrated:

  • LYLsunD3 LYLmicro™ in spray form is recommended for rapid elimination of vitamin D deficiency in COVID-19 patients.
  • LYLsunD3 LYLmicro™ effectively reduces inflammation markers in COVID-19 patients.

The randomized comparative group study demonstrated:

  • for overweight and obese individuals, overall blood levels of vitamin D increase by 112% already after one month of use of LYLsunD3 LYLmicro™.
  • for people over 50 years of age, overall blood levels of vitamin D increase by 95% already after one month of use of LYLsunD3 LYLmicro™.

Randomized, placebo controlled, independent study on the positive, quantifiable effect of the LYL love your life® sunD3 LYLmicro™ sublingual spray on the levels of vitamin D3 in the blood and inflammatory markers (CRP, fibrinogen, ferritin, IL-6) in COVID-19 patients

Overview of clinical study

The aim of the study

The aim of the study was to identify vitamin D accumulation properties in hospitalized COVID-19 patients, while also identifying changes in inflammatory markers for subjects taking vitamin D and the placebo group.

Materials and methods

Protocol number of study: 2021sunD3LYLmicro™SARS-CoV-2

Start of study: 1 February 2021

End of study: 13 June 2021

Location of the study: Pauls Stradiņš Clinical University Hospital, Riga, Latvia

Head researcher: Prof. Valdis Pīrāgs

Inclusion criteria: hospitalized patients aged ≥ 18 with a positive SARS – CoV – 2 RNS test, vitamin D blood levels of < 30 ng/ml, voluntary consent by the subject to participate in the study

The subjects were divided into 2 groups:

  • Treatment group: COVID-19 patients whose vitamin D level was < 30 ng/ml and who took the assayable spray form of vitamin D sublingually 4,000IU/3x/d after a meal in the morning, midday and evening, shaking the product well prior to use.
  • Control group: COVID-19 patients whose vitamin D level was < 30 ng/ml and who took a placebo sublingually 3x/d after a meal in the morning, midday and evening, shaking the product well prior to use.

Results

Overall, the study analyzed 300 hospitalized COVID-19 patients who had been hospitalized with mild to severe illness. Based on exclusion criteria, 100 patients qualified for the study. All patients were randomly divided into two groups. The first group (treatment group) was given vitamin D3 (cholecalciferol) in spray form, while the other (control group) was given a placebo spray. The first group consisted of 48 patients, the control group consisted of 52 patients.

Image 1. Changes in patients’ C-reactive protein (CRP) depending on treatment

General conclusions

  • Vitamin D in spray form is an optional preparation for rapidly eliminating a vitamin D deficiency in hospitalized patients of the COVID-19 pneumonia and other acute inflammatory disease.
  • Vitamin D in spray form effectively reduces the level of inflammatory marker CRP in patients of the COVID-19 pneumonia, especially when combined with dexamethasone (see Image 1).

Randomized comparative group study on the effects of LYL love your life® sunD3 LYLmicro™ sublingually applicable spray on blood levels of vitamin D3 as compared to other forms of vitamin D3 (oil drops and capsules)

Overview of clinical study

The aim of the study

The aim of the study was to determine the overall efficiency of vitamin D3 accumulation in the body in proportion to dosage and length of use across three vitamin D3 products on different bases and with different application methods.

Materials and methods

Protocol number of study: 2021sunD3LYLmicro™ formula comparison

Start of study: 1 April 2021

End of study: 1 June 2021

Head researcher: Prof. Valdis Pīrāgs

Inclusion criteria:  men and women aged 18 to 65 with blood levels of vitamin D < 30 ng/ml, subject’s voluntary consent to participate in the study, the subject commits to not use other formulations containing vitamin D during the study.

The subjects were divided into 3 groups:

  • The spray group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D sublingually in spray form immediately after their morning meal, having first shaken the product well.
  • The oil drop group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D in oil drop form immediately after their morning meal.
  • The capsule group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D in capsule form immediately after their morning meal.

Results

140 subjects were invited to the initial study interview, based on test results and exclusion criteria, 99 subjects qualified for the study and were divided into three groups at random with a similar number of subjects in each group.

Image 1. Overall changes in vitamin D concentration in the serum for subjects with BMI ≥ 25 kg/m2
Image 2. Overall changes in vitamin D concentration in the serum for subjects aged ≥ 50

General conclusions

  • For overweight and obese individuals (BMI ≥ 25 kg/m2) with a vitamin D deficiency taking 4,000 IUs of vitamin D3 in spray form daily resulted in an average increase of 112% of their total vitamin D concentration in the serum over a period of only 30 days. (see Image 1).
  • For the population aged ≥ 50 with a vitamin D deficiency taking 4,000 IUs of vitamin D3 in spray form daily resulted in an average increase of 95% of their total vitamin D concentration in the serum over a period of only 30 days. (see Image 2).
  • Taken sublingually, vitamin D in spray form quickly enters the capillary bloodstream and is available to the body at a higher concentration, therefore it is recommended for eliminating in a rapid and controlled manned vitamin D deficiencies in people with a heightened risk of malabsorption, especially older overweight and obese individuals.

Randomized, placebo controlled, independent study on the positive, quantifiable effect of LYL love your life® sunD3 LYLmicro™ on the levels of vitamin D3 in the blood

Overview of clinical study

The aim of the study

The aim of the study was to determine the overall accumulation efficiency in the body of vitamin D based on usage dose and duration, as well as to compare the relative differences in accumulation in the body of two different vitamin D3 products with different base formulations. In addition, these indicators were also correlated with eating habits and lifestyle.

Materials and methods

Study approved by: Research Ethics Committee of the Institute of Cardiology and Regenerative Medicine of the University of Latvia

Start of study: 10 February 2020

End of study: 12 March 2020

Head researcher: Prof. Aleksejs Derovs

Exclusion criteria: pregnant women, underaged individuals, persons with mental disabilities, use of additional dietary supplements, as well as persons, whose initial level of vitamin D did not comply with the requirements for the study

The subjects were divided into 3 groups:

  • Group A: subjects whose vitamin D level was 5 ng/ml and who took cholecalciferol integrated in a microemulsion (LYLmicro™) 4,000IU/2x/d after a meal in the morning and evening, shaking the product well prior to use.
  • Group B: subjects whose vitamin D level was 2 ng/ml and who took cholecalciferol integrated in nano particles (LYL EFFUSIO®) 4,000IU/2x/d after a meal in the morning and evening, shaking the product well prior to use.
  • Control group: subjects whose vitamin D level was 9 ng/ml and who took a placebo 2x/d after a meal in the morning and evening, shaking the product well prior to use.

Results

158 subjects (males and female, aged 18 to 60) were invited to the initial study interview. Based on the exclusion criteria, 111 subjects qualified for the study and were randomly divided into three groups, where group A consisted of 41 subjects, group B consisted of 43 subjects, and the control group consisted of 27 subjects.

Image 1. Overall changes in vitamin D concentration in the serum by group at the end of the study
Image 2. Changes in vitamin D levels for groups A and B at the end of the study

General conclusions

  • Vitamin D in spray form, used twice a day (8,000 IUs) over the course of one month raises the overall concentration of vitamin D in the serum by an average of 132% (see Image 1).
  • If vitamin D is not supplemented, the concentration of vitamin D in the serum falls by an average of 15% over the course of one month (see Image 1).
  • Vitamin D3 (cholecalciferol) integrated into the LYLmicro™ and LYL EFFUSIO® spray form correlates with a high adherence as the overall levels of vitamin D in the serum increased for 92% of subjects by the end of the study (see Image 2).

*For more details about the study, see:

Prof. Aleksejs Derovs, “Randomizēta, placebo kontrolēta pētījuma rezultāti par dažādu D vitamīna spreja formu ietekmi uz D vitamīna līmeni asinīs”, magazine “Latvijas ārsts”, November 2020 issue.

In vitro assessment of the absorption efficiency of vitamin D3 (cholecalciferol) in oral spray form

Overview of clinical study

The aim of the study

The aim of the study was to investigate the permeability and safety in the mucus membranes of the mouth of various vitamin D3 aerosols available on the market, at various intervals and to demonstrate the buccal-sublingual absorption of the active substance cholecalciferol (vitamin D3).

Materials and methods

Location of the study: Laboratory of Bioanalytical methods and Biodosimetry of the Faculty of Biology of the University of Latvia

Lead researcher: Prof. Aleksejs Derovs

Results

For the relative comparison among various samples of the efficiency of cholecalciferol (vitamin D3) diffusion, a vertical diffusion cell automatic system was selected, using cellulose membranes as a barrier. Time points selected: at 30 minutes and slightly later at 3 hours, as well as at 16 hours.

Grafiskās ilustrācijas EN v2-01
Image 1. Migration results for assayable samples of vitamin D3 at all time points

General conclusions

  • The best result for vitamin D3 migration through cellulose membranes at all tested time points were demonstrated by the LYLmicro™ formula (see Image 1).
  • The assayed compositions containing vitamin D3 do not have a significant negative effect on the viability of epithelial tissue in the mucous membranes of the mouth, which demonstrates the safety of the formulations.

*For more details about the study, see:

Prof. Aleksejs Derovs, “Dažādu D3 vitamīna formu uzsūkšanās efektivitātes analīze”, magazine “Latvijas ārsts”, October 2020 issue